The New England journal of medicine, 2019-03, Vol.380 (11), p.1001-1011
- Swindells, Susan
- Ramchandani, Ritesh
- Gupta, Amita
- Benson, Constance A
- Leon-Cruz, Jorge
- Mwelase, Noluthando
- Jean Juste, Marc A
- Lama, Javier R
- Valencia, Javier
- Omoz-Oarhe, Ayotunde
- Supparatpinyo, Khuanchai
- Masheto, Gaerolwe
- Mohapi, Lerato
- da Silva Escada, Rodrigo O
- Mawlana, Sajeeda
- Banda, Peter
- Severe, Patrice
- Hakim, James
- Kanyama, Cecilia
- Langat, Deborah
- Moran, Laura
- Andersen, Janet
- Fletcher, Courtney V
- Nuermberger, Eric
- Chaisson, Richard E
2019
Details
- Autor(en) / Beteiligte
- Swindells, Susan
- Ramchandani, Ritesh
- Gupta, Amita
- Benson, Constance A
- Leon-Cruz, Jorge
- Mwelase, Noluthando
- Jean Juste, Marc A
- Lama, Javier R
- Valencia, Javier
- Omoz-Oarhe, Ayotunde
- Supparatpinyo, Khuanchai
- Masheto, Gaerolwe
- Mohapi, Lerato
- da Silva Escada, Rodrigo O
- Mawlana, Sajeeda
- Banda, Peter
- Severe, Patrice
- Hakim, James
- Kanyama, Cecilia
- Langat, Deborah
- Moran, Laura
- Andersen, Janet
- Fletcher, Courtney V
- Nuermberger, Eric
- Chaisson, Richard E
- Titel
- One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
- Ist Teil von
- The New England journal of medicine, 2019-03, Vol.380 (11), p.1001-1011
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Treatment of latent tuberculosis infection is an important control measure, especially in patients coinfected with HIV. In this international phase 3 trial, 1 month of isoniazid plus rifapentine was noninferior to the standard 9 months of isoniazid in HIV-infected patients.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1806808Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6563914
- Format
- –
- Schlagworte
- Acquired immune deficiency syndrome, Adult, AIDS, AIDS-Related Opportunistic Infections - prevention & control, Allergies, Antiretroviral drugs, Antiretroviral therapy, Antitubercular Agents - administration & dosage, Antitubercular Agents - adverse effects, CD4 antigen, CD4 Lymphocyte Count, Clinical trials, Disease prevention, Dosage and administration, Drug Administration Schedule, Drug dosages, Drug therapy, Drug Therapy, Combination, Evidence-based medicine, Female, Field representatives, Health aspects, HIV, HIV Infections - complications, HIV Infections - drug therapy, HIV patients, Human immunodeficiency virus, Humans, Infections, Infectious diseases, Isoniazid, Isoniazid - administration & dosage, Isoniazid - adverse effects, Laboratories, Latent Tuberculosis - complications, Latent Tuberculosis - drug therapy, Male, Medication Adherence, Patients, Pharmaceuticals, Prevention, Rifampin - administration & dosage, Rifampin - adverse effects, Rifampin - analogs & derivatives, Rifapentine, Tuberculosis, Tuberculosis - prevention & control